Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience
In healthy adults (n = 55) greater cortical thickness of the rostral anterior cingulate, but not the caudal or posterior cingulate, predicted higher scores on the emotional subscales of the 5D-ASC after controlling for age and sex. This finding implies that individual differences in brain structure help explain variability in emotional responses to psilocybin, extending the traditional set-and-setting account.
Authors
- Franz Vollenweider
- Katrin Preller
Published
Abstract
Psilocybin is the psychoactive compound of mushrooms in the psilocybe species. Psilocybin directly affects a number of serotonin receptors, with highest affinity for the serotonin 2A receptor (5HT-2Ar). Generally, the effects of psilocybin, and its active metabolite psilocin, are well established and include a range of cognitive, emotional, and perceptual perturbations. Despite the generality of these effects, there is a high degree of inter-individual variability in subjective psilocybin experiences that are not well understood. Others have shown brain morphology metrics derived from magnetic resonance imaging (MRI) can predict individual drug response. Due to high expression of serotonin 2A receptors (5HT-2Ar) in the cingulate cortex, and its prior associations with psilocybin, we investigate if cortical thickness of this structure predicts the psilocybin experience in healthy adults. We hypothesized that greater cingulate thickness would predict higher subjective ratings in sub-scales of the Five-Dimensional Altered State of Consciousness (5D-ASC) with high emotionality in healthy participants (n = 55) who received oral psilocybin (either low dose: 0.160 mg/kg or high dose: 0.215 mg/kg). After controlling for sex, age, and using false discovery rate (FDR) correction, we found the rostral anterior cingulate predicted all four emotional sub-scales, whereas the caudal and posterior cingulate did not. How classic psychedelic compounds induce such large inter-individual variability in subjective states has been a long-standing question in serotonergic research. These results extend the traditional set and setting hypothesis of the psychedelic experience to include brain structure metrics.
Research Summary of 'Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience'
Introduction
Lewis and colleagues situate their study in a long history of serotonin and psychedelic research, noting that psilocybin is converted in vivo to psilocin and primarily acts at the 5-HT2A receptor. Previous work has established broad cognitive, perceptual, and emotional effects of psilocybin, but substantial inter- and intra-individual variability in subjective responses remains poorly explained. The authors note that historical explanations emphasise "set and setting" (personality, expectation, and environment), yet biological predictors — including brain morphological measures that have predicted other drug responses and psychiatric treatment outcomes — have been less explored in the psychedelic literature. The study therefore aimed to test whether cortical thickness of limbic regions with high 5-HT2A receptor expression predicts the emotional component of the psilocybin experience in healthy adults. Using the Five-Dimensional Altered States of Consciousness scale (5D-ASC), the investigators focused on four emotionally valenced subscales (Feeling of Unity, Blissful State, Spiritual Experience, and Insightfulness) and hypothesised that greater cingulate cortical thickness would be associated with larger psilocybin-induced changes on these subscales.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Lewis, C. R., Preller, K. H., Braden, B. B., Riecken, C., & Vollenweider, F. X. (2020). Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience. Biomedicines, 8(2), 34. https://doi.org/10.3390/biomedicines8020034
References (29)
Papers cited by this study that are also in Blossom
Hasler, F., Ludewig, S. · Journal of Psychopharmacology (2008)
Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)
Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O. et al. · Neuropsychopharmacology (1999)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)
Pokorny, T., Preller, K. H., Kometer, M. et al. · International Journal of Neuropsychopharmacology (2017)
Show all 29 referencesShow fewer
Vollenweider, F. X., Csomor, P. A., Knappe, B. et al. · Neuropsychopharmacology (2007)
Kraehenmann, R., Schmidt, A., Friston, K. et al. · NeuroImage (2015)
Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Thomas, K., Malcolm, B., Lastra, D. · Journal of Psychoactive Drugs (2017)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Cited By (9)
Papers in Blossom that reference this study
Prugger, J., Hirschfeld, T., Majic, T. et al. · Neuropsychopharmacology (2023)
Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Zamani, A., Carhart-Harris, R. L., Christoff, K. · Neuropsychopharmacology (2021)
Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)
Hirschfeld, T., Schmidt, T. T. · Journal of Psychopharmacology (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Kelly, J. R., Crockett, M. T., Alexander, L. et al. · Irish Journal of Psychological Medicine (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.